Drugs / MMI-0100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02515396 | Jul 2015 → Mar 2016 | — | Moerae Matrix, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMI-0100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02515396 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3809901 ↗ |
| Route | Inhaled | “5 days once daily (qd) dose of MMI-0100 or placebo administered by inhalation” NCT02515396 ↗ |